Loading organizations...
§ Private Profile · Zürich, Zurich, Switzerland
Synthetic biology company engineering microbes to biomanufacture high-purity, low-cost chemicals and biochemicals for food, cosmetics, and pharma.
Based in Pudong, Shanghai, China, Cataya is a synthetic biology company that engineers microbes and develops clean fermentation processes to biomanufacture chemical and biochemical products. The enterprise utilizes renewable plant-based materials to produce high-value molecules, including terpenoids, amino acids, and oligosaccharides, for commercial applications across the food, cosmetics, personal care, and pharmaceutical sectors. To support its strain engineering and automation capabilities, the business has raised approximately $34.42 million in total venture funding. This capitalization includes a 250 million yuan Series B round and a prior Series A+ round backed by prominent institutional investors such as Eight Roads Ventures, Sequoia China, F-Prime Capital, and Source Code. The organization is currently expanding its operational footprint by planning additional research units in the United States and Japan. Cataya was founded in 2021 by former Amyris executive Lishan Zhao.
Cataya has raised $13.7M across 1 funding round.
Cataya has raised $13.7M in total across 1 funding round.
Cataya has raised $13.7M across 1 funding round. Most recently, it raised $13.7M Series A in October 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 23, 2023 | $13.7M Series A | Betty CAI, Hongshan Capital Group (Sequoia Capital China) | Bits X Bites, F Prime Capital, Source Code Capital | Announced |
Cataya has raised $13.7M in total across 1 funding round.
Cataya's investors include Betty Cai, Hongshan Capital Group (Sequoia Capital China), Bits x Bites, F-Prime Capital, Source Code Capital.